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Conclusion: CNS bacteraemia is most commonly 
associated with intravenous catheter infection, which 
was predominantly seen. Oro-pharyngeal colonization 
does account for a significant (29.4%) incidence of 
bacteraemia in the compromised host including neutro- 
penic and bone marrow transplant (autograft) recipients. 
Hence, prophylaxis with antibiotic is essential. 
A break up of the percentage of bacterial isolates to 
be presented. 
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Dendritic cells are rare cells that are principally involved 
in the presentation of antigen and stimulation of T 
lymphocytes. In chemotherapy treatment of neoplasms 
is bind with depreciated of immunological potential of 
patient. Development and function of dendritic cells 
may be inhibited by cytokines produced by cancer cells. 
The total number of 34 patients: 23 males and 11 
females, aged from 16 months to 17 years (median 11 
years) treated in the Department of Children Oncology 
and Hematology Medical University of Wroclaw, Poland 
(ALL-15 AML-9, NHL-2, HD-5, LCAL-3 children) 
were examined. Peripheral blood was collect at time of 
diagnosis and during chemotherapy and analyzed with 
used flow cytometric analysis. Concentration of a 
dendritic cells (CDllc+HLA DR+CD83+ CD86+) 
were examined. Phenotypic populations of elementary 
lymphocytes (CD3, CD4, CD8, CD16, CD19, CD56) 
with take into consideration markers of activation 
CD23, CD26, CD28, HLA-DR was analyzed. 
The dendritic cells were examined with use of specific 
markers for distinct blood dendritic cell populations: 
BDCA-1 (antigen presented on CD1lchish and CD123’“” 
dendritic cells with monocytoid morphology); BDCA-2 
(expression on CDllc- and CD123’ dendritic cells with 
plasmocytoid morphology); BDCA-3 (expression on 
CDlldim and CD123- dendritic cells with monocytoid 
morphology). 
The results of our study showed decreased level of 
blood the dendritic cells in our patients in comparison 
with control group of healthy children. 
Results of study were compared with reply of 
antineoplasm treatment. 
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Candida guilliermondii is rarely isolated from humans, 
but is considered a part of the emerging opportunistic 
fungi being recovered more frequently from severely 
immunocompromised patients. From January 1988 to 
December 1998 we identified 9 patients with C. guillier- 
mondii fungemia at our center. Most of the fungemias 
(5/9) occurred as a breakthrough infection on antifungal 
prophylaxis with agents such as fluconazole, Iiposomal 
amphotericin B, and itraconazole. Five of the 9 patients 
acquired the infection during their hospital stay 10-45 
days after admission and were considered as noso- 
comial, while the remaining 4 patients acquired the 
infection endogenously within O-4 days following admis- 
sion. Nosocomial fungemia was associated with hemato- 
logical malignancy most often occurring in leukemia 
patients in relapse, prior intensive chemotherapy, 
profound neutropenia, mucositis, steroid therapy, and 
concomitant multiple bacterial and fungal sepsis. Non- 
nosocomial fungemias were more often associated with 
solid tumors or hematological malignancy in remission, 
without steroids or mucositis, Both groups were treated 
with azoles and amphotericin compounds with variable 
outcomes. Four of the five patients in the nosocomial 
group died, while the only patient who survived had 
catheter-related fungemia. In contrast, all of the non- 
nosocomial cases survived the fungemia despite the fact 
that half of them (2/4) did not receive any treatment. 
Within the limitations of a small number, nosocomial 
C. guilliermondii fungemia occurring in the setting of 
hematologic malignancy and profound neutropenia 
is often a breakthrough infection with poor outcome 
despite aggressive antifungal therapy. 
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Between January 1993 and May 1998, we identified 
76 immunocompromised cancer patients (pts) with 
Candida glabrata fungemia. With the widespread use 
of fluconazole prophylaxis in 1992 at our center, the 
incidence of C. glabrata fungemia increased. Most im- 
munocompromised cancer pts with C. glabrata fungemia 
